Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma

Bibliography

• Spivey TL, De Giorgi V, Zhao Y, et al. The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics 2012;13:156
   PubMed Web of Science ®Google Scholar
• Ibrahim N, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 2009;4:551-79
   PubMedGoogle Scholar
• Palmieri G, Capone M, Ascierto ML, et al. Main roads to melanoma. J Transl Med 2009;7:86
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
   PubMed Web of Science ®Google Scholar
• Colombino M, Lissia A, Capone M, et al. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med 2013;11:202
   PubMed Web of Science ®Google Scholar
• Tomei S, Civini S, Bedognetti D, et al. The immune-related role of BRAF mutation in melanoma [abstract p788]. J Immuno Therapy of Cancer 2012;23:9
   Google Scholar
• Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20
   PubMed Web of Science ®Google Scholar
• Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004;122:342-8
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012:30(Suppl): abstract 8502
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013;31:3205-11
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012;10:85
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Avaialable from http://clinicaltrial.gov/)
   Google Scholar
• Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Meier F, Garbe C. Protein kinase inhibitors in melanoma. Expert Opin Pharmacother 2013;14(16):2195-201
   PubMed Web of Science ®Google Scholar
• Benjamin RS. Chemotherapy of malignant melanoma. World J Surg 1979;3:321-8
   PubMedGoogle Scholar
• Luce JK. Chemotherapy of malignant melanoma. Cancer 1972;30:1604-15
   PubMed Web of Science ®Google Scholar
• Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011;16:5-24
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14
   PubMed Web of Science ®Google Scholar
• Henary H, Hong DS, Falchook GS, et al. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol 2013;24(8):2158-65
   PubMed Web of Science ®Google Scholar
• Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-32
   PubMed Web of Science ®Google Scholar
• Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012;30:2522-9
   PubMed Web of Science ®Google Scholar
• Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: new insights and new therapies. J Invest Dermatol 2012;132:854-63
   PubMed Web of Science ®Google Scholar
• Yoshida H, Kunisada T, Grimm T, et al. Review: melanocyte migration and survival controlled by SCF/c-kit expression. J Investig Dermatol Symp Proc 2001;6:1-5
   PubMed Web of Science ®Google Scholar
• Hochhaus A. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Ann Hematol 2004;83(Suppl 1):S65-6
   Google Scholar
• Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821-8
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34
   PubMed Web of Science ®Google Scholar
• Natali PG, Nicotra MR, Winkler AB, et al. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992;52:197-201
   PubMed Web of Science ®Google Scholar
• Shen SS, Zhang PS, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 2003;30:539-47
   PubMed Web of Science ®Google Scholar
• Tomei S, Mazzanti C, Marchetti I, et al. c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules. J Transl Med 2012;10:7
   PubMed Web of Science ®Google Scholar
• Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007;13:4874-81
   PubMed Web of Science ®Google Scholar
• Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12:2622-7
   PubMed Web of Science ®Google Scholar
• Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81
   PubMed Web of Science ®Google Scholar
• Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398-405
   PubMed Web of Science ®Google Scholar
• Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99:734-40
   PubMed Web of Science ®Google Scholar
• Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005-11
   PubMed Web of Science ®Google Scholar
• Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012;12:349-61
   PubMedGoogle Scholar
• Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013;10:588-98
   PubMed Web of Science ®Google Scholar
• Antonescu CR. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 2011;223:251-61
   PubMed Web of Science ®Google Scholar
• Schlegel J, Sambade MJ, Sather S, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest 2013;123:2257-67
   PubMed Web of Science ®Google Scholar
• Albino AP, Le Strange R, Oliff AI, et al. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature 1984;308:69-72
   PubMed Web of Science ®Google Scholar
• Milagre C, Dhomen N, Geyer FC, et al. A mouse model of melanoma driven by oncogenic KRAS. Cancer Res 2010;70:5549-57
   PubMed Web of Science ®Google Scholar
• Tomei S, Adams S, Uccellini L, et al. Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population. Med Oncol 2012;29:3456-61
   PubMed Web of Science ®Google Scholar
• COSMIC (Catalogue Of Somatic Mutations In Cancer. Available from: http://cancer.sanger.ac.uk/cancergenome/projects/cosmic
   Google Scholar
• Posch C, Ortiz-Urda S. NRAS mutant melanoma–undrugable? Oncotarget 2013;4:494-5
   PubMedGoogle Scholar
• Niessner H, Beck D, Sinnberg T, et al. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J Invest Dermatol 2011;131:468-79
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Salama AK, Niedzwiecki D, et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med 2012;10:246
   PubMed Web of Science ®Google Scholar
• Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106:20411-16
   PubMed Web of Science ®Google Scholar
• Salama AK, Kim KB. MEK Inhibition in the treatment of advanced melanoma. Curr Oncol Rep 2013;15:473-82
   PubMedGoogle Scholar
• Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18:555-67
   PubMed Web of Science ®Google Scholar
• Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 2013;14:733-40
   PubMed Web of Science ®Google Scholar
• Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-9
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14:249-56
   PubMed Web of Science ®Google Scholar
• Lebbe C, Lesimple T, Raymond E, et al. Pimasertib (MSC1936369B/AS703026), a selective oral MEK1/2 inhibitor, shows clinical activity in cutaneous and uveal metastatic melanoma in the phase I program [abstract C07]. EADO 2012 Annual Meeting; 2012
   Google Scholar
• Basile KJ, Abel EV, Dadpey N, et al. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors. Cancer Res 2013;73(23):7101-10
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7
   PubMed Web of Science ®Google Scholar
• Morris EJ, Jha S, Restaino CR, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013;3:742-50
   PubMed Web of Science ®Google Scholar
• Wangari-Talbot J, Chen S. Genetics of melanoma. Front Genet 2012;3:330
   PubMedGoogle Scholar
• Madhunapantula SV, Robertson GP. Therapeutic Implications of Targeting AKT Signaling in Melanoma. Enzyme Res 2011;2011:327923
   PubMedGoogle Scholar
• Knight ZA, Shokat KM. Chemically targeting the PI3K family. Biochem Soc Trans 2007;35:245-9
   PubMed Web of Science ®Google Scholar
• Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005;104:1045-8
   PubMed Web of Science ®Google Scholar
• Margolin KA, Moon J, Flaherty LE, et al. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res 2012;18:1129-37
   PubMed Web of Science ®Google Scholar
• Werzowa J, Koehrer S, Strommer S, et al. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J Invest Dermatol 2011;131:495-503
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83
   PubMed Web of Science ®Google Scholar
• Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012;11:909-20
   PubMed Web of Science ®Google Scholar
• Posch C, Moslehi H, Feeney L, et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci USA 2013;110:4015-20
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Lebbe C, Robert C, et al. Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA). J Clin Oncol 2011;29(Suppl): abstract 8531
   Google Scholar
• Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-61
   PubMed Web of Science ®Google Scholar
• Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957-9
   PubMed Web of Science ®Google Scholar
• Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007;14:2367-76
   PubMed Web of Science ®Google Scholar
• Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012;30:34-41
   PubMed Web of Science ®Google Scholar
• Minor DR. Bevacizumab advanced melanoma (BEAM) was a positive trial. J Clin Oncol 2012;30:2023; author reply 2023-2024
   PubMed Web of Science ®Google Scholar
• Del Vecchio M, Mortarini R, Canova S, et al. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010;16:5862-72
   PubMed Web of Science ®Google Scholar
• Hodi FS, Friedlander PA, Atkins MB, et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2011;29(Suppl): abstract 8511
   Google Scholar
• Flaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2013;31:373-9
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30
   PubMed Web of Science ®Google Scholar
• Fruehauf J, Lutzky J, McDermott D, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res 2011;17:7462-9
   PubMed Web of Science ®Google Scholar
• Hong DS, Koetz BS, Kurzrock R, et al. Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors. J Clin Oncol 2010;28:15s(Suppl): abstract 2540
   Google Scholar
• Corrie PG, Basu B, Zaki KA. Targeting angiogenesis in melanoma: prospects for the future. Ther Adv Med Oncol 2010;2:367-80
   PubMedGoogle Scholar
• Ascierto ML, De Giorgi V, Liu Q, et al. An immunologic portrait of cancer. J Transl Med 2011;9:146
   Google Scholar
• Shimanovsky A, Jethava A, Dasanu CA. Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opin Biol Ther 2013;13:1413-27
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012;18:1386-94
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Meng Y, Harlin H. Immune Suppression in the tumor microenvironment. J Immunother 2006;29:233-40
   PubMed Web of Science ®Google Scholar
• Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci USA 2010;107:11906-11
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:1169-88
   PubMed Web of Science ®Google Scholar
• Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477-82
   PubMed Web of Science ®Google Scholar
• Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:5610-18
   PubMed Web of Science ®Google Scholar
• Joseph RW, Sullivan RJ, Harrell R, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 2012;35:66-72
   PubMed Web of Science ®Google Scholar
• Dummer R, Hauschild A, Guggenheim M, et al. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v194-7
   PubMed Web of Science ®Google Scholar
• Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009;27:2645-52
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhou J, Dong Z, et al. Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. J Immuno Ther Cancer 2013;1(Suppl 1):P247
   Google Scholar
• Panelli MC, Wang E, Phan G, et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002;3:RESEARCH0035
   PubMedGoogle Scholar
• Panelli MC, White R, Foster M, et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2004;2:17
   PubMedGoogle Scholar
• Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002;62:3581-6
   PubMed Web of Science ®Google Scholar
• Weiss GR, Grosh WW, Chianese-Bullock KA, et al. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011;17:7440-50
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Wang E, Sertoli MR, Marincola FM. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010;9:555-65
   PubMed Web of Science ®Google Scholar
• Blanchard T, Srivastava PK, Duan F. Vaccines against advanced melanoma. Clin Dermatol 2013;31:179-90
   PubMed Web of Science ®Google Scholar
• Mocellin S, Rossi CR, Nitti D, et al. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. Biochim Biophys Acta 2003;1653:61-71
   PubMed Web of Science ®Google Scholar
• Lens M. The role of vaccine therapy in the treatment of melanoma. Expert Opin Biol Ther 2008;8:315-23
   PubMed Web of Science ®Google Scholar
• Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine 2007;25(Suppl 2):B4-16
   PubMed Web of Science ®Google Scholar
• Ascierto ML, Worschech A, Yu Z, et al. Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer 2011;11:451
   PubMed Web of Science ®Google Scholar
• Reinboth J, Ascierto ML, Chen NG, et al. Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates. Hum Gene Ther Methods 2012;23:285-96
   Google Scholar
• Wang E, Phan GQ, Marincola FM. T-cell-directed cancer vaccines: the melanoma model. Expert Opin Biol Ther 2001;1:277-90
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-80
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Immunol 2007;178:2617-21
   PubMed Web of Science ®Google Scholar
• Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-7
   PubMed Web of Science ®Google Scholar
• Alexandrescu DT, Ichim TE, Riordan NH, et al. Immunotherapy for melanoma: current status and perspectives. J Immunother 2010;33:570-90
   PubMedGoogle Scholar
• Wang E, Selleri S, Sabatino M, et al. Spontaneous and treatment-induced cancer rejection in humans. Expert Opin Biol Ther 2008;8:337-49
   PubMed Web of Science ®Google Scholar
• Wang E, Bedognetti D, Marincola FM. Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol 2013;31:2369-71
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013;342:967-70
   PubMed Web of Science ®Google Scholar
• Wang E, Bedognetti D, Tomei S, Marincola FM. Common pathways to tumor rejection. Ann NY Acad Sci 2013;1284:75-9
   PubMed Web of Science ®Google Scholar
• Wang E, Tomei S, Marincola FM. Reflections upon human cancer immune responsiveness to T cell-based therapy. Cancer Immunol Immunother 2012;61:761-70
   PubMed Web of Science ®Google Scholar
• Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013;39:11-26
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011;239:27-44
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
   PubMed Web of Science ®Google Scholar
• Stein WD, Gulley JL, Schlom J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011;17:907-17
   PubMed Web of Science ®Google Scholar
• Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012;104:599-613
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. Deciphering and reversing tumor immune Suppression. Immunity 2013;39:61-73
   PubMed Web of Science ®Google Scholar
• Salerno EP, Shea SM, Olson WC, et al. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunol Immunother 2013;62:1149-59
   PubMed Web of Science ®Google Scholar
• Hailemichael Y, Dai Z, Jaffarzad N, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 2013;19:465-72
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Spivey TL, Zhao Y, et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer 2013;109:2412-23
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17:1290-7
   PubMed Web of Science ®Google Scholar
• Uccellini L, De Giorgi V, Zhao Y, et al. IRF5 gene polymorphisms in melanoma. J Transl Med 2012;10:170
   PubMed Web of Science ®Google Scholar
• Wang E, Zhao Y, Monaco A, et al. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One 2012;7:e40805
   Google Scholar
• Parmiani G, Cimminiello C, Maccalli C. Increasing immunogenicity of cancer vaccines to improve their clinical outcome. Expert Rev Vaccines 2013;12:1111-13
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27
   PubMed Web of Science ®Google Scholar
• Kruit WH, Suciu S, Dreno B, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 2013;31:2413-20
   PubMed Web of Science ®Google Scholar
• Ulloa-Montoya F, Louahed J, Dizier B, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013;31:2388-95
   PubMed Web of Science ®Google Scholar
• Brichard VG. Selection of patients for cancer immunotherapy. Society for immunotherapy of cancer 2013 Annual Meeting, oral presentation
   Google Scholar
• Kaufman HL. Vaccines for melanoma and renal cell carcinoma. Semin Oncol 2012;39:263-75
   Google Scholar
• Andtbacka R, Collichio FA, Amatruda T, et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 2013;31(Suppl): abstract LBA9008
   PubMed Web of Science ®Google Scholar
• Chowdhery R, Gonzalez R. Immunologic therapy targeting metastatic melanoma: allovectin-7. Immunotherapy 2011;3:17-21
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Maguire HC Jr, et al. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22:403-15
   PubMed Web of Science ®Google Scholar
• Gottardi R, Douradinha B. Carbon nanotubes as a novel tool for vaccination against infectious diseases and cancer. J Nanobiotechnology 2013;11:30
   PubMed Web of Science ®Google Scholar
• Pescatori M, Bedognetti D, Venturelli E, et al. Functionalized carbon nanotubes as immunomodulator systems. Biomaterials 2013;34:4395-403
   PubMed Web of Science ®Google Scholar
• Delogu LG, Vidili G, Venturelli E, et al. Functionalized multiwalled carbon nanotubes as ultrasound contrast agents. Proc Natl Acad Sci USA 2012;109:16612-17
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269-81
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013;31:999-1008
   PubMed Web of Science ®Google Scholar
• Wang XY, Zuo D, Sarkar D, Fisher PB. Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother 2011;12:2695-706
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64
   PubMed Web of Science ®Google Scholar
• Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science 1995;270:932-3
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-65
   PubMed Web of Science ®Google Scholar
• Maio M, Bondarenko I, Robert C, et al. Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (IPI) + dacarbazine (DTIC) on Phase 3 study CA184-024. Ann Oncol 23(9s Suppl): abstract 1127P
   Google Scholar
• Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013;24:2174-80
   PubMed Web of Science ®Google Scholar
• Maio M, Di Giacomo AM, Robert C, Eggermont AM. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol 2013;25:166-72
   Google Scholar
• Hamid O, Hwu W, Richards J, et al. Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results. J Clin Oncol2012;30(Suppl): abstract 8508
   Google Scholar
• Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012;13:879-86
   PubMed Web of Science ®Google Scholar
• Patel SP, Hwu W, Kim KB, et al. Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma. J Clin Oncol 2012;30(Suppl): abstract 8514
   Google Scholar
• Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20
   PubMed Web of Science ®Google Scholar
• Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31:616-22
   PubMed Web of Science ®Google Scholar
• Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol 2010;37:450-4
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Cherian J, Moschos SJ, et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012;30:322-8
   PubMed Web of Science ®Google Scholar
• Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013;14:1104-11
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-8
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44
   PubMed Web of Science ®Google Scholar
• Sznol M, Kluger H, Hodi FS, et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol2013;31(Suppl): abstract CRA9006
   Google Scholar
• Hamid O, Sosman J, Lawrence D, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol 2013;31(Suppl): abstract 9010
   PubMed Web of Science ®Google Scholar
• Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013;19:997-1008
   PubMed Web of Science ®Google Scholar
• Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004;4:420-31
   PubMed Web of Science ®Google Scholar
• Redmond WL, Weinberg AD. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol 2007;27:415-36
   PubMed Web of Science ®Google Scholar
• Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68
   PubMed Web of Science ®Google Scholar
• Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 2010;28:57-78
   PubMed Web of Science ®Google Scholar
• Curti BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients. Cancer Res 2013;73:7189-98
   PubMed Web of Science ®Google Scholar
• Redmond WL, Triplett T, Floyd K, Weinberg AD. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression. PLoS One 2012;7:e34467
   Google Scholar
• French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-53
   PubMed Web of Science ®Google Scholar
• Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999;5:774-9
   PubMed Web of Science ®Google Scholar
• Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780-7
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013;19:1035-43
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007;25:876-83
   PubMed Web of Science ®Google Scholar
• Spranger S, Gajewski T. Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment. J Immuno Ther Cancer 2013;1(Suppl 1):O8
   Google Scholar
• Brignone C, Gutierrez M, Mefti F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 2010;8:71
   PubMed Web of Science ®Google Scholar
• Poirier N, Haudebourg T, Brignone C, et al. Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+)) -activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates. Clin Exp Immunol 2011;164:265-74
   PubMed Web of Science ®Google Scholar
• Roychoudhuri R, Hirahara K, Mousavi K, et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature 2013;498:506-10
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7
   PubMed Web of Science ®Google Scholar
• Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012;18:6758-70
   PubMed Web of Science ®Google Scholar
• Besser MJ, Shapira-Frommer R, Itzhaki O, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 2013;19:4792-800
   PubMed Web of Science ®Google Scholar
• Dudley ME, Gross CA, Somerville RP, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 2013;31:2152-9
   PubMed Web of Science ®Google Scholar
• Phan GQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control 2013;20:289-97
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Wang E, Sato-Matsushita M, et al. Molecular profiling of immunotherapeutic resistance. In: Prendergsat GC, Jaffee EM, editors, Cancer immunotherapy, immune suppression and tumor growth. 2nd edition. Elsevier, 2013.
   Google Scholar
• Fisher B, Packard BS, Read EJ, et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989;7:250-61
   PubMed Web of Science ®Google Scholar
• Spivey TL, Uccellini L, Ascierto ML, et al. Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med 2011;9:174
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Marincola FM. Combination therapy: the next opportunity and challenge of medicine. J Transl Med 2011;9:115
   PubMed Web of Science ®Google Scholar
• Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995;13:1110-22
   PubMed Web of Science ®Google Scholar
• Daponte A, Signoriello S, Maiorino L, et al. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-alpha in advanced malignant melanoma. J Transl Med 2013;11:38
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lee SJ, McDermott DF, et al. Multicenter, randomized phase II trial of GM-CSF plus ipilimumab versus ipi alone in metastatic melanoma. J Clin Oncol 2013;31(Suppl): abstract CRA9007
   PubMedGoogle Scholar
• Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18:2039-47
   PubMed Web of Science ®Google Scholar
• Marincola FM. The trouble with translational medicine. J Intern Med 2011;270:123-7
   PubMed Web of Science ®Google Scholar
• Simon R. Novel clinical trial designs for development of immunotherapy combinations. SITC Cancer Immunotherapy Clinical Trials: Concepts and Challenges Meeting 2013, oral presentation
   Google Scholar
• Yang Y, Lizee G, Hwu P. Strong emerging rationale for combining oncogene-targeted agents with immunotherapy. Oncoimmunology 2013;2:e22730
   Google Scholar
• Ribas A, Hersey P, Middleton MR, et al. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 2012;18:336-41
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013;39:74-88
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol 2013;25:291-6
   PubMed Web of Science ®Google Scholar
• Castelli C, Sensi M, Lupetti R, et al. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. Cancer Res 1994;54:4785-90
   PubMed Web of Science ®Google Scholar
• Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006;203:1651-6
   PubMed Web of Science ®Google Scholar
• Khalili JS, Liu S, Rodriguez-Cruz TG, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012;18:5329-40
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19:1225-31
   PubMed Web of Science ®Google Scholar
• Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013;19:393-403
   PubMed Web of Science ®Google Scholar
• Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70:5213-19
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365-6
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33
   PubMed Web of Science ®Google Scholar
• Murtas D, Maric D, De Giorgi V, et al. IRF-1 responsiveness to IFN-gamma predicts different cancer immune phenotypes. Br J Cancer 2013;109:76-82
   PubMed Web of Science ®Google Scholar
• Hamid O, Schmidt H, Nissan A, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011;9:204
   PubMed Web of Science ®Google Scholar
• Ji RR, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012;61:1019-31
   PubMed Web of Science ®Google Scholar
• Carretero R, Wang E, Rodriguez AI, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2012;131:387-95
   PubMed Web of Science ®Google Scholar
• Panelli MC, Stashower ME, Slade HB, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007;8:R8
   PubMed Web of Science ®Google Scholar
• Wang E, Uccellini L, Marincola FM. A genetic inference on cancer immune responsiveness. Oncoimmunology 2012;1:520-5
   PubMed Web of Science ®Google Scholar